MGMireia Guerau-De-Arellano

Mireia Guerau-De-Arellano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mireia Guerau-De-Arellano has a total of 121 co-authors. Here are the top co-authors by number of shared publications:

  • Shouvonik Sengupta

    School of Health and Rehabilitation Sciences, The Ohio State University , Columbus, OH

    5 shared publications
  • Stephanie A. Amici

    Division of Medical Laboratory Science, Wexner Medical Center, School of Health and Rehabilitation Sciences

    5 shared publications
  • Stephanie A. Amici

    Division of Medical Laboratory Science, School of Health and Rehabilitation Sciences, The Ohio State University , Columbus, OH

    4 shared publications
  • Kyle A Jablonski

    Division of Medical Laboratory Science, School of Health and Rehabilitation Sciences, College of Medicine, The Ohio State University , Columbus, OH 43210

    3 shared publications
  • Lindsay M. Webb

    School of Health and Rehabilitation Sciences, Division of Medical Laboratory Science, College of Medicine, Wexner Medical Center

    3 shared publications
  • Stephanie A Amici

    Division of Medical Laboratory Science, School of Health and Rehabilitation Sciences, College of Medicine, The Ohio State University , Columbus, OH 43210

    3 shared publications

Latest Publications

  • Neuroimmune interactions in health and disease

    by Matthew A. Sherman, Deborah L. Hodge, Qian Liu, Ryan T. Ranallo, Margaret A. Morris, Mireia Guerau-De-Arellano


  • Meeting report: Hidden links in autoimmunity

    by Mireia Guerau-De-Arellano, Margaret A. Morris, Matthew A. Sherman, Thomas R. Esch

    A NIAID-sponsored workshop was held in September 2024, where challenges to understanding common mechanisms in autoimmune disease were discussed as opportunities to advance research.


  • PRMT5 Promotes T follicular helper Cell Differentiation and Germinal Center Responses during Influenza Virus Infection

    by Kaitlin A Read, Stephanie A Amici, Sadaf Farsi, Madeline Cutcliffe, Bella Lee, Chan-Wang Jerry Lio, Hsin-Jung Joyce Wu, Mireia Guerau-De-Arellano, Kenneth J. Oestreich

    Protein arginine methyltransferases (PRMTs) modify diverse protein targets and regulate numerous cellular processes; yet, their contributions to individual effector T cell responses during infections are incompletely understood. In this study, we identify PRMT5 as a critical regulator of CD4+ T follicular helper cell (Tfh) responses during influenza virus infection in mice. Conditional PRMT5 deletion in murine T cells results in an almost complete ablation of both Tfh and T follicular regulatory populations and, consequently, reduced B cell activation and influenza-specific Ab production. Supporting a potential mechanism, we observe elevated surface expression of IL-2Rα on non–T regulatory effector PRMT5-deficient T cells. Notably, IL-2 signaling is known to negatively impact Tfh differentiation. Collectively, our findings identify PRMT5 as a prominent regulator of Tfh programming, with potential causal links to IL-2 signaling.


  • Sterols and immune mechanisms in asthma

    by Rodney D. Britt, Ned Porter, Mitchell H. Grayson, Kymberly M. Gowdy, Megan Ballinger, Kara Wada, Hye-Young Kim, Mireia Guerau-De-Arellano


  • Sterols in asthma

    by Mireia Guerau-De-Arellano, Rodney D. Britt


  • Open Access

    Akt isoforms in the immune system

    by Mireia Guerau-De-Arellano, Zayda L. Piedra-Quintero, Philip N. Tsichlis

    Akt is a PI3K-activated serine-threonine kinase that exists in three distinct isoforms. Akt’s expression in most immune cells, either at baseline or upon activation, reflects its importance in the immune system. While Akt is most highly expressed in innate immune cells, it plays crucial roles in both innate and adaptive immune cell development and/or effector functions. In this review, we explore what’s known about the role of Akt in innate and adaptive immune cells. Wherever possible, we discuss the overlapping and distinct role of the three Akt isoforms, namely Akt1, Akt2, and Akt3, in immune cells.


  • Open Access

    PRMT5 in T Cells Drives Th17 Responses, Mixed Granulocytic Inflammation, and Severe Allergic Airway Inflammation

    by Brandon W. Lewis, Stephanie A Amici, Hye-Young Kim, Emily M. Shalosky, Aiman Q. Khan, Joshua Walum, Kymberly M. Gowdy, Joshua A Englert, Ned A Porter, Mitchell H. Grayson, et al.

    Severe asthma is characterized by steroid insensitivity and poor symptom control and is responsible for most asthma-related hospital costs. Therapeutic options remain limited, in part due to limited understanding of mechanisms driving severe asthma. Increased arginine methylation, catalyzed by protein arginine methyltransferases (PRMTs), is increased in human asthmatic lungs. In this study, we show that PRMT5 drives allergic airway inflammation in a mouse model reproducing multiple aspects of human severe asthma. We find that PRMT5 is required in CD4+ T cells for chronic steroid-insensitive severe lung inflammation, with selective T cell deletion of PRMT5 robustly suppressing eosinophilic and neutrophilic lung inflammation, pathology, airway remodeling, and hyperresponsiveness. Mechanistically, we observed high pulmonary sterol metabolic activity, retinoic acid-related orphan receptor γt (RORγt), and Th17 responses, with PRMT5-dependent increases in RORγt’s agonist desmosterol. Our work demonstrates that T cell PRMT5 drives severe allergic lung inflammation and has potential implications for the pathogenesis and therapeutic targeting of severe asthma.


  • Open Access

    The Minority Scientists’ Experience: Challenging and Overcoming Barriers to Enhancing Diversity and Career Advancement

    by Tonya J. Webb, Mireia Guerau-De-Arellano, Harlan P. Jones, Cherié L. Butts, Luis Sanchez-Perez, Luis J. Montaner

    Minority groups face barriers in accessing quality health care, professional advancement, and representation in immunology research efforts as a result of institutional racism that if unaddressed can perpetuate a lack of diversity. In 2021, the AAI Minority Affairs Committee convened a cross section of academic and industry scientists from underrepresented groups at various stages of their professions to discuss how best to address the toll racism takes on study design and scientific careers. Panelists drew directly from their own experiences as scientists to share perspectives and strategies for countering a lack of representation in clinical research, responding to microaggressions, navigating academic advancement, and providing effective mentorship. The session reinforced the need for minority scientists to take an active role in advocating for diversity, engaging mentors, and taking responsibility to face rather than avoid institutional obstacles. Overall, increased dialogue and institutional awareness of the experience of scientists from underrepresented groups in research remain the best tools to ensure a health equity mindset and advancement of their careers.


  • Open Access

    PRMT5 Promotes Symmetric Dimethylation of RNA Processing Proteins and Modulates Activated T Cell Alternative Splicing and Ca2+/NFAT Signaling

    by Shouvonik Sengupta, Kelsi O West, Shridhar Sanghvi, Georgios Laliotis, Laura M. Agosto, Kristen W. Lynch, Philip N. Tsichlis, Harpreet Singh, Kristin L. Patrick, Mireia Guerau-De-Arellano

    Protein arginine methyltransferase (PRMT) 5 is the type 2 methyltransferase catalyzing symmetric dimethylation of arginine. PRMT5 inhibition or deletion in CD4 Th cells reduces TCR engagement-induced IL-2 production and Th cell expansion and confers protection against experimental autoimmune encephalomyelitis, the animal model of multiple sclerosis. However, the mechanisms by which PRMT5 modulates Th cell proliferation are still not completely understood, and neither are the methylation targets in T cells. In this manuscript, we uncover the role of PRMT5 on alternative splicing in activated mouse T cells and identify several targets of PRMT5 symmetric dimethylation involved in splicing. In addition, we find a possible link between PRMT5-mediated alternative splicing of transient receptor potential cation channel subfamily M member 4 (Trpm4) and TCR/NFAT signaling/IL-2 production. This understanding may guide development of drugs targeting these processes to benefit patients with T cell–mediated diseases.


  • Open Access

    PRMT5 in T cells drives Th17 responses, mixed granulocytic inflammation and severe allergic airway inflammation

    by Brandon W. Lewis, Stephanie A. Amici, Hye-Young Kim, Emily Shalosky, Aiman Khan, Joshua Walum, Kymberly M. Gowdy, Joshua A. Englert, Ned A. Porter, Mitchell H. Grayson, et al.

    Severe asthma is characterized by steroid insensitivity and poor symptom control, and is responsible for the majority of asthma-related hospital costs. Therapeutic options remain limited, in part due to limited understanding in mechanisms driving severe asthma. Increased arginine methylation, catalyzed by protein arginine methyltransferases (PRMTs), is increased in asthmatic lungs. Here, we show that PRMT5 drives allergic airway inflammation in a mouse model reproducing multiple aspects of human severe asthma. We find that PRMT5 is required in CD4 + T cells for chronic steroid-insensitive severe lung inflammation, with selective T cell deletion of PRMT5 robustly suppressing eosinophilic and neutrophilic lung inflammation, pathology, airway remodeling and hyperresponsiveness. Mechanistically, we observed high pulmonary sterol metabolic activity, ROR-γt and Th17 responses, with PRMT5-dependent increases in ROR-γt’s agonist desmosterol. Our work demonstrates that T cell PRMT5 drives severe allergic lung inflammation and has potential implications for the pathogenesis and therapeutic targeting of severe asthma.